Position in ABUS
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$211,593
+$126,671 QoQ
Shares Held
44,082
+19.4% QoQ
Ownership
0.022%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#92
of 175 holders
Holding Since
Dec 2020
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABUS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. ABUS ranks #125 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IOVA |
Iovance Biotherapeutics, Inc.
|
655,318 | $2,726,122 | |
| 2 | IMVT |
Immunovant, Inc.
|
65,267 | $2,514,737 | |
| 3 | GOSS |
Gossamer Bio, Inc.
|
14,986,947 | $2,472,846 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
9,419 | $2,305,488 | |
| 5 | CABA |
Cabaletta Bio, Inc.
|
668,563 | $2,079,230 | |
| 6 | MLTX |
MoonLake Immunotherapeutics
|
106,695 | $2,077,351 | |
| 7 | ATYR |
aTYR PHARMA INC
|
3,454,863 | $2,062,553 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
23,257 | $2,022,196 |
All Filings in ABUS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $211,593 | 44,082 | Shares | Sole | 2026-08-06 | |
| 2023-06-30 | $84,922 | 36,923 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $115,624 | 38,160 | Shares | Sole | 2023-05-12 | |
| 2022-12-31 | $273,055 | 117,191 | Shares | Sole | 2023-02-13 | |
| 2022-09-30 | $181,068 | 94,800 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $43,728 | 16,136 | Shares | Sole | 2022-08-09 | |
| 2022-03-31 | $96,709 | 32,453 | Shares | Sole | 2022-05-11 | |
| 2021-03-31 | $1,031,763 | 309,839 | Shares | Sole | 2021-05-10 | |
| 2020-12-31 | $93,084 | 26,221 | Shares | Sole | 2021-02-03 | |
| No filing history on record for this holder in this stock. | ||||||